Zealand Pharma A/S (NASDAQ:ZLDPF) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Zacks has also assigned Zealand Pharma A/S an industry rank of 122 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised Zealand Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th.

Shares of Zealand Pharma A/S (NASDAQ ZLDPF) opened at $16.05 on Friday. Zealand Pharma A/S has a fifty-two week low of $14.95 and a fifty-two week high of $19.51.

TRADEMARK VIOLATION NOTICE: “Zacks: Zealand Pharma A/S (ZLDPF) Receives Average Recommendation of “Strong Buy” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/04/zacks-zealand-pharma-as-zldpf-receives-average-recommendation-of-strong-buy-from-analysts.html.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZLDPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.